IN2012DN01964A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01964A
IN2012DN01964A IN1964DEN2012A IN2012DN01964A IN 2012DN01964 A IN2012DN01964 A IN 2012DN01964A IN 1964DEN2012 A IN1964DEN2012 A IN 1964DEN2012A IN 2012DN01964 A IN2012DN01964 A IN 2012DN01964A
Authority
IN
India
Prior art keywords
metformin
amount
disclosed
subject
chemotherapeutic agents
Prior art date
Application number
Other languages
English (en)
Inventor
Kevin Struhl
Heather Hirsch
Dimitrios Iliopoulos
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of IN2012DN01964A publication Critical patent/IN2012DN01964A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1964DEN2012 2009-08-25 2010-08-25 IN2012DN01964A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23677809P 2009-08-25 2009-08-25
PCT/US2010/046616 WO2011031474A2 (en) 2009-08-25 2010-08-25 Use of metformin in cancer treatment and prevention

Publications (1)

Publication Number Publication Date
IN2012DN01964A true IN2012DN01964A (ja) 2015-08-21

Family

ID=43733025

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1964DEN2012 IN2012DN01964A (ja) 2009-08-25 2010-08-25

Country Status (14)

Country Link
US (1) US20120220664A1 (ja)
EP (1) EP2470170A4 (ja)
JP (1) JP2013503171A (ja)
KR (1) KR20120080579A (ja)
CN (1) CN102596192A (ja)
AU (1) AU2010292599A1 (ja)
BR (1) BR112012004281A2 (ja)
CA (1) CA2772120A1 (ja)
IL (1) IL218287A0 (ja)
IN (1) IN2012DN01964A (ja)
MX (1) MX2012002337A (ja)
SG (1) SG178556A1 (ja)
WO (1) WO2011031474A2 (ja)
ZA (1) ZA201201434B (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130040310A1 (en) * 2009-12-15 2013-02-14 Salk Institute For Biological Studies Ulk1 compositions, inhibitors, screening and methods of use
EP2648734B1 (en) * 2010-12-06 2019-02-13 Cure Cancer Worldwide LLC Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
WO2012171015A2 (en) * 2011-06-10 2012-12-13 Translational Genomics Research Institute Therapeutic combination for cancer treatment
CN102327256B (zh) * 2011-09-22 2014-01-29 上海交通大学医学院附属瑞金医院 二甲双胍在制备治疗淋巴瘤疾病药物中的应用
WO2013086002A1 (en) * 2011-12-05 2013-06-13 Cellworks Research India Private Limited Compositions, process of preparation of said compositions and method of treating cancer
JP6513576B2 (ja) * 2013-01-14 2019-05-15 ヘルス クリニックス リミテッド 抗がん剤および使用
SG11201509707QA (en) * 2013-04-12 2015-12-30 Rebecca Lambert Bent Cancer therapy
JP6242071B2 (ja) * 2013-04-23 2017-12-06 国立大学法人 岡山大学 免疫疲弊ｃｄ８＋ｔ細胞の機能改善薬、がん治療薬及びメタボリック症候群の予防または治療薬
EP3003296B1 (en) * 2013-05-24 2018-10-10 Research Institute for Nutrition and Aging Co., Ltd. Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
CN107205968B (zh) * 2014-08-14 2021-08-20 威斯康星州医药大学股份有限公司 修饰的线粒体-二甲双胍化合物及其合成和使用方法
EP3192517A4 (en) * 2014-08-19 2018-04-25 National University Corporation Okayama University Method for enhancing immune cell function and method for assessing immune cell multifunctionality
WO2016026933A1 (en) * 2014-08-21 2016-02-25 Centre National De La Recherche Scientifique - Cnrs - Adjuvant or neoadjuvant therapy for sensitizing cancer stem cells to chemotherapy
JP7189020B2 (ja) * 2016-02-16 2022-12-13 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ 癌のエピジェネティックプロファイリング
WO2018044369A2 (en) 2016-05-19 2018-03-08 The Regents Of The University Of California Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
CN106727468A (zh) * 2017-04-01 2017-05-31 四川大学 二甲双胍及联合二甲双胍和长春新碱在制备治疗白血病药物中的应用及药物组合物
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
CA3060509A1 (en) 2017-04-21 2018-10-25 Federica Sotgia Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
CR20190524A (es) 2017-05-19 2020-01-10 Lunella Biotech Inc Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
WO2019183003A1 (en) * 2018-03-18 2019-09-26 The University Of North Carolina At Chapel Hill Methods and assays for endometrial diseases
CN117338938A (zh) * 2019-02-28 2024-01-05 北京强新生物科技有限公司 用于治疗中枢神经系统紊乱的组合疗法
KR102312100B1 (ko) * 2020-06-05 2021-10-14 (주)프론트바이오 항바이러스제 및 항우울제를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513465A (ja) * 2004-09-15 2008-05-01 ザ プレジデント アンド フェロウズ オブ ハーバード カレッジ 肥満及び糖尿病の治療におけるｅｒストレス低減
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
DE102006026026A1 (de) * 2006-06-01 2007-12-06 Grünenthal GmbH Arzneimittel
WO2008097861A2 (en) * 2007-02-02 2008-08-14 Braincells, Inc. MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS
WO2008110491A2 (en) * 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
WO2009101199A2 (en) * 2008-02-15 2009-08-20 Bodo Melnik Treatment of acne vulgaris; rosacea and rhinophym

Also Published As

Publication number Publication date
JP2013503171A (ja) 2013-01-31
EP2470170A4 (en) 2013-01-02
CA2772120A1 (en) 2011-03-17
MX2012002337A (es) 2012-06-25
WO2011031474A3 (en) 2011-06-16
EP2470170A2 (en) 2012-07-04
SG178556A1 (en) 2012-03-29
ZA201201434B (en) 2013-05-29
AU2010292599A1 (en) 2012-03-15
BR112012004281A2 (pt) 2016-03-08
US20120220664A1 (en) 2012-08-30
CN102596192A (zh) 2012-07-18
IL218287A0 (en) 2012-04-30
WO2011031474A2 (en) 2011-03-17
KR20120080579A (ko) 2012-07-17

Similar Documents

Publication Publication Date Title
IN2012DN01964A (ja)
IL258880A (en) Compounds of diarylhydantoin
TW200621240A (en) Cancer treatments
MX365138B (es) Inhibidores de prolil hidroxilasa.
EP1876893A4 (en) TREATMENT OF CANCER BY THE COMBINED INHIBITION OF PROTEASOME AND TELOMERASE ACTIVITIES
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
MY158106A (en) Inhibitors of e1 activating enzymes
HK1139863A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
WO2011056021A3 (ko) 벤조헤테로사이클 유도체의 암 예방 및 치료 또는 암 전이 억제를 위한 용도
PH12014501639A1 (en) Pharmaceutical compositions and methods
MX2013010770A (es) Tratamiento de tumores solidos.
MY169330A (en) Method for inhibition of deubiquitinating activity
SG163595A1 (en) Use of tocotrienol composition for the prevention of cancer
WO2009105217A3 (en) Complement inhibitors as therapeutic agents for treatment of cancer
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
WO2006060819A3 (en) Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
WO2009158526A3 (en) Methods of reducing cellular proliferation by inhibiting acsvl3
EP1547596A4 (en) MEDICAL COMPOSITION AND METHOD FOR THE TREATMENT OF MALIGNANT TUMORS AND THE USE THEREOF
EA200970418A1 (ru) Применение мультитаргетного ингибитора киназ для лечения или предупреждения рака головного мозга
NZ604127A (en) Neuroendocrine tumor treatment using mtor inhibitors
WO2006085033A3 (fr) Compositions pharmaceutiques destinees au traitement du cancer de la prostate
MXNL05000001A (es) Conjugados de carbohidrato-somatostina-14.
UA101610C2 (ru) Наночастица, которая содержит рапамицин и альбумин, в качестве противоракового агента